Compositions and treatments based on cadherin modulation
AssigneeCoDa Therapeutics, Inc.
InventorsBRADFORD J. DUFT, DAVID L. BECKER
Life of this patent
Estimating the term…
Abstract
Anti-cadherin and anti-ZO-1 agents and compositions, and kits containing them for use in the promotion and/or improvement of wound healing and/or tissue repair, and for anti-scarring, anti-inflammatory, anti-fibrosis and anti-adhesion indications.
Claims16
A polynucleotide, optionally an antisense polynucleotide, an RNA, shRNA, miRNA or an siRNA, to a messenger RNA (mRNA) encoding a protein that is a member of the cadherin protein superfamily, optionally a human cadherin protein, optionally a cadherin protein selected from the group consisting of N-cadherin, E-cadherin, P-cadherin, cadherin 11, cadherin 12, a protocadherin protein, a desmoglein protein, and a desmocollin protein, wherein the polynucleotide optionally is between about 5 and about 100 nucleotides in length, optionally about 6 to about 40 nucleotides in length.
Dependencies are inferred from the claim text.